Integra LifeSciences Holdings Corporation (IART)
NASDAQ: IART · Real-Time Price · USD
21.80
+0.09 (0.41%)
Dec 20, 2024, 4:00 PM EST - Market closed
IART Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 1,565 | 1,542 | 1,558 | 1,542 | 1,372 | 1,518 | Upgrade
|
| Revenue Growth (YoY) | 1.45% | -1.03% | 0.99% | 12.43% | -9.60% | 3.06% | Upgrade
|
| Cost of Revenue | 632.4 | 593.66 | 575.63 | 597.81 | 520.83 | 564.68 | Upgrade
|
| Gross Profit | 932.52 | 947.92 | 982.03 | 944.64 | 851.03 | 952.88 | Upgrade
|
| Selling, General & Admin | 633.79 | 592.64 | 613.83 | 637.45 | 594.53 | 687.6 | Upgrade
|
| Research & Development | 91.34 | 82.84 | 81.52 | 93.05 | 77.38 | 79.57 | Upgrade
|
| Operating Expenses | 738.65 | 687.86 | 709.23 | 744.66 | 699.66 | 788.44 | Upgrade
|
| Operating Income | 193.87 | 260.06 | 272.8 | 199.98 | 151.37 | 164.44 | Upgrade
|
| Interest Expense | -65.4 | -51.38 | -49.59 | -50.4 | -71.58 | -53.96 | Upgrade
|
| Interest & Investment Income | 19.7 | 17.2 | 11.92 | 6.74 | 9.3 | 10.78 | Upgrade
|
| Currency Exchange Gain (Loss) | -30.49 | -36.31 | 16.13 | - | -1.6 | -0.3 | Upgrade
|
| Other Non Operating Income (Expenses) | 36.03 | 39.17 | -8.3 | 19.31 | 6.03 | 9.82 | Upgrade
|
| EBT Excluding Unusual Items | 153.71 | 228.74 | 242.96 | 175.63 | 93.52 | 130.78 | Upgrade
|
| Merger & Restructuring Charges | -1.05 | -1.05 | -7.15 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | 0.64 | 41.8 | - | - | Upgrade
|
| Asset Writedown | -11.7 | - | - | -2.75 | - | -5.76 | Upgrade
|
| Other Unusual Items | -152.88 | -146.62 | -22.56 | - | - | - | Upgrade
|
| Pretax Income | -11.92 | 81.07 | 213.89 | 214.68 | 93.52 | 60.1 | Upgrade
|
| Income Tax Expense | -5.38 | 13.33 | 33.34 | 45.6 | -40.37 | 9.9 | Upgrade
|
| Earnings From Continuing Operations | -6.55 | 67.74 | 180.55 | 169.08 | 133.89 | 50.2 | Upgrade
|
| Net Income | -6.55 | 67.74 | 180.55 | 169.08 | 133.89 | 50.2 | Upgrade
|
| Net Income to Common | -6.55 | 67.74 | 180.55 | 169.08 | 133.89 | 50.2 | Upgrade
|
| Net Income Growth | - | -62.48% | 6.79% | 26.28% | 166.71% | -17.43% | Upgrade
|
| Shares Outstanding (Basic) | 77 | 80 | 83 | 85 | 85 | 86 | Upgrade
|
| Shares Outstanding (Diluted) | 77 | 80 | 84 | 85 | 85 | 86 | Upgrade
|
| Shares Change (YoY) | -5.37% | -3.81% | -2.30% | 0.30% | -1.46% | 2.97% | Upgrade
|
| EPS (Basic) | -0.08 | 0.85 | 2.18 | 2.00 | 1.58 | 0.59 | Upgrade
|
| EPS (Diluted) | -0.09 | 0.84 | 2.16 | 1.98 | 1.57 | 0.58 | Upgrade
|
| EPS Growth | - | -61.11% | 9.09% | 26.11% | 170.69% | -19.44% | Upgrade
|
| Free Cash Flow | 38.04 | 73.09 | 222.13 | 264.41 | 164.94 | 161.9 | Upgrade
|
| Free Cash Flow Per Share | 0.49 | 0.91 | 2.66 | 3.09 | 1.94 | 1.87 | Upgrade
|
| Gross Margin | 59.59% | 61.49% | 63.05% | 61.24% | 62.03% | 62.79% | Upgrade
|
| Operating Margin | 12.39% | 16.87% | 17.51% | 12.97% | 11.03% | 10.84% | Upgrade
|
| Profit Margin | -0.42% | 4.39% | 11.59% | 10.96% | 9.76% | 3.31% | Upgrade
|
| Free Cash Flow Margin | 2.43% | 4.74% | 14.26% | 17.14% | 12.02% | 10.67% | Upgrade
|
| EBITDA | 321.06 | 383.57 | 391.1 | 319.82 | 267.4 | 273.9 | Upgrade
|
| EBITDA Margin | 20.52% | 24.88% | 25.11% | 20.73% | 19.49% | 18.05% | Upgrade
|
| D&A For EBITDA | 127.19 | 123.51 | 118.3 | 119.84 | 116.03 | 109.46 | Upgrade
|
| EBIT | 193.87 | 260.06 | 272.8 | 199.98 | 151.37 | 164.44 | Upgrade
|
| EBIT Margin | 12.39% | 16.87% | 17.51% | 12.97% | 11.03% | 10.84% | Upgrade
|
| Effective Tax Rate | - | 16.44% | 15.59% | 21.24% | - | 16.48% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.